UBS initiated coverage with a ‘Buy’ rating and set a $1,250 price target, citing confidence in Lilly’s obesity execution.

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

The weight loss drug Wegovy is now available as a tablet in more than 70,000 U.S. pharmacies as well as select telehealth ...

Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection.

The convenience and lower cost of the oral pill may be critical to some patients, which could expand the market, improve ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

The FDA-approved weight loss drug offers an oral alternative to invasive injections with similar effectiveness.